• UCB reported BE BOLD trial results showing Bimzelx maintained numerically greater joint improvements than Skyrizi through 24 weeks in psoriatic arthritis.
• Earlier results, presented at EULAR 2026, demonstrated statistically significant superiority for Bimzelx in joint responses at 16 weeks.
• Full 24-week results will be presented November 10 at the 2026 ACR Convergence in Orlando, Florida.
• Secondary outcomes remained numerically better without statistical significance; complete skin clearance was comparable between treatments at 24 weeks.
• Overall safety was comparable, except for more mild-to-moderate localized Candida infections with Bimzelx; no new safety signals emerged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.